Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Nasal Fentanyl and Oral Transmucosal Fentanyl (Actiq) in Cancer Breakthrough Pain (FT-019-IM)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adult in- or out patient with cancer and breakthrough pain; using a stable, chronic opioid treatment for background pain.~* Minimum three BTP episodes per week and maximum four per day. Life expectancy of at least three months.~* Chemotherapy and palliative radiotherapy (except facial radiotherapy) are allowed.~* Randomisation in previous studies with NF, i.e. FT-016-IM, FT-017-IM or FT-018-IM, is not allowed.~* Previous use of Actiq is accepted.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).